Dial
This article was originally published in The Rose Sheet
Executive Summary
After-tax impairment charge of $43 mil. will be taken in first quarter due to instability in Argentina and changes in accounting procedure, Dial Chief Financial Officer Rad Conrad says during Merrill Lynch conference March 19-20. Separately, Dial is presented with the Catalyst Blue Ribbon Board designation as one of 317 companies in the Fortune 1,000 with more than one female board member. Catalyst is a national organization for the advancement of women in business...
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.